

Sub B1
Amended

2

crude fimbrial agglutinin² solution by precipitating fimbrial agglutinogens 2 and 3 from the clarified supernatant by the addition of a polyethylene glycol to the clarified supernatant, separating the precipitated fimbrial agglutinin 2 and 3 from the resulting supernatant and solubilizing the separated fimbrial agglutinogens 2 and 3; and
(f) purifying fimbrial agglutinogens 2 and 3 from the crude fimbrial agglutinin solution to produce the fimbrial agglutinin preparation comprising fimbrial agglutinogens 2 and 3.

Q2 2. (Amended) The process of claim 1 [2] wherein the temperature is about 80°C.

Q3 3. (Amended) The process of claim 1 [3]; wherein the time is about 30 minutes.

Q4 4. (Amended) The process of claim 1 [2] wherein the first supernatant is concentrated prior to the incubation step (d).

Q5
Sub B2
10. (Amended) The process of claim 1 [8] wherein said precipitation is effected by adding polyethylene glycol of molecular weight about 8000 to the clarified supernatant to a concentration of about 3% to about 5 wt. to effect precipitation of said agglutinogens from the clarified supernatant.

Q6
13. (Amended) The process of claim 12 wherein said column chromatography includes Sephadex [Septhadex] 6B and/or PEI silica column chromatography.

Cancel claims 2, 4, 6, 8, 9 and 18 to 37.

REMARKS

Sub B3
Petition is hereby made under the provisions of 37 C.F.R. 1.136(a) for an extension of three months of the period for response to the Office Action on this case. Our cheque in the amount of the prescribed fee is enclosed.

The Examiner indicated that the claims are directed to three different inventions. In response to a telephone call from the Examiner, the applicants made a provisional election with traverse to prosecute the claims of Group I, namely claims 1 to 17. The applicants now confirm that election and have deleted claims 18 to 37, namely the non-elected claims from this application. Such deletion is made without prejudice to

55